Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109104 · ClinicalTrials.gov registry record · NA
Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products
A NA study of Sunscreening Agents, sponsored by HALEON.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT05109104: Completed NA study of Sunscreening Agents, sponsored by HALEON.
NCT05109104 is a NA study of Sunscreening Agents that has completed, run by HALEON. The registered enrollment target is 13 participants, below the 81-participant average among 21 other Sunscreening Agents trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05109104, a NA study of Sunscreening Agents, has completed, sponsored by HALEON.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the static SPF of three sunscreen products (ChapStick Active Performance \[CAP\] UnScented, CAP Herbal Mint and CAP Mountain Berry) using the methodology described in the Food and Drug Administration (FDA) Final Rule (2011).
Primary Outcome
SPF values for each test product and the SPF standard were first calculated for each individual participant:SPFi = MEDp/MEDuR (p=protected \[treated\] site; u=unprotected \[untreated\] site). The arithmetic mean SPF, standard deviation (SD) and standard error (SE) were then calculated separately for each test product and the SPF standard from valid SPFi data: SPF = (ΣSPFi)/n; SD = √\[(ΣSPFi\^2) - ((ΣSPFi)\^2/n) /(n-1))\]; SE = SD/√n (n = number participants providing valid test results). For SPF
Conditions Studied
Interventions
- DRUG CAP UnScented
- DRUG CAP Herbal Mint
- DRUG CAP Mountain Berry
- DRUG SPF Standard Sunscreen
Study Locations (1)
North Carolina
- GSK Investigational Site - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-11-08 |
| Est. Completion | 2021-12-15 |
| Phase | NA |
What the finished NCT05109104 record still lists
NCT05109104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 81-participant average among 21 other Sunscreening Agents trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Sunscreening Agents appearing as the primary indexed condition, and to 4 interventions - of which CAP UnScented is the first listed.
NCT05109104 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05109104 about?
NCT05109104 is a clinical study titled "Clinical Study to Evaluate the Sun Protection Factor (SPF) of Three Sunscreen Products". The purpose of this study is to determine the static SPF of three sunscreen products (ChapStick Active Performance \[CAP\] UnScented, CAP Herbal Mint and CAP Mountain Berry) using the methodology described in the Food and Drug Administration (FDA) Final Rule (2011).
What is the current status of trial NCT05109104?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2021-11-08. Estimated completion is 2021-12-15.
What conditions does trial NCT05109104 study?
This clinical trial studies the following conditions: Sunscreening Agents.
What interventions are being tested in trial NCT05109104?
The interventions under investigation include: CAP UnScented (DRUG), CAP Herbal Mint (DRUG), CAP Mountain Berry (DRUG), SPF Standard Sunscreen (DRUG).
Who is sponsoring clinical trial NCT05109104?
This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05109104 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sunscreening Agents
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05109104's enrollment target sits among peer trials
13 12th of 21 higher than 9 of 21 other Sunscreening Agents trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sunscreening Agents trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Sunscreen Dispensers in Parks Visited by Teenagers
ACTIVE NOT RECRUITING · NA
-
To Assess the Safety of a Sunscreen Product
COMPLETED · NA
-
Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821/2016)
COMPLETED · NA
-
Sun Protection Factor Assay (SPF Assay 204/2016)
COMPLETED · NA
-
18794 - Human Photo Toxicity Test
COMPLETED · NA
-
Sun Protection Factor Assay
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI